NanoRegMed Ltd is a UK biotechnology company. Based in the London BioScience Innovation Centre, we create and bring to market innovative materials and components for materials for a wide variety of applications.
We are commercialising a new family of biodegradable and non-biodegradable graphene-based nanocomposites, Hastalextm and BioHastalextm that help repair or replace damaged or missing organs and are superior to any other material available today. We also licence our materials and collaborate with other companies for non-medical applications.
Our spin-out company, Nanoloom Limited, is using some of these materials to create fibre for textiles and other applications. Find out more at www.nanoloom.co.uk.
In light of COVID-19 we have shifted our focus to help where we can, including to produce hand sanitizer.
- World Health Organisation recommended formula
- 75% alcohol
- Non-sticky and dries in seconds
- Available in different bottle sizes
- Made in the UK under strict quality control conditions
- Has passed UK regulatory and certification requirements
To make a request or inquiry, please contact us directly at info@nanoregmed.com.
We are committed to providing premium quality innovative materials and services to our customers and partners
rGO and FGO
NanoRegMed produces reduced graphene oxide and functionalised graphene oxide with superior levels of functionalisation certified by the UK National Physical Laboratory
Graphene-based Nanocomposites
Our unique materials Hastalextm and BioHastalextm can be tailored for various applications with properties like extreme strength, conductivity, elasticity and hydrophobicity
R&D Services
NanoRegMed can act as an R&D partner on projects and grant applications globally and in a variety of fields.
Professor Alex Seifalian
Lead Scientist
Alex is a professor of nanotechnology and regenrative medicine. His current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer.
Hana Salussolia
CEO
Hana worked in financial services for over 15 years and held senior positions in leading global investment banks. She specialised in commercialising new ideas, opening new markets and creating new products. Her strategies successfully generated significant revenue streams in areas where there was zero income before.
Stephen Hancock
Chemist
Stephen has 30+ years work experience in the industry, including with ICI Pharmaceuticals Ltd, Cardiotech Ltd, Rosehill Polymers Ltd, Pilkington Optronics Ltd and many more.
London BioScience Innovation Center
2 Royal College St
London, United Kingdom
NW1 0NH